Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.48 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.48 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.44 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.40 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | FYN | P06241 | 1/20 | 0.37 |
| ▸ | GLO1 | Q04760 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.36 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13222027 | 0.84 | RECQL (0.43) | MAPTSMN1; SMN2RECQLPDE1APDE1B | |
| SCHEMBL13510674 | 0.82 | CYP2A6 (0.50) | CYP2A6CYP2B6CYP2E1ADORA1ADORA2A | |
| SCHEMBL14270967 | 0.82 | KDR (0.43) | CYP2A6GAA | |
| SCHEMBL8212283 | 0.81 | CYP2A6 (0.53) | CYP2A6CYP2B6CYP2E1ADORA1ADORA2A | |
| SCHEMBL13509080 | 0.76 | ALDH1A1 (0.43) | ADORA1ADORA2APTGER1CYP3A4CYP2C9 | |
| SCHEMBL14270968 | 0.75 | ALDH1A1 (0.48) | ADORA1ADORA2ACYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13509018 | 0.74 | PDPK1 (0.53) | CYP2A6ADORA1ADORA2AMAPT | |
| SCHEMBL13509079 | 0.73 | MAPK14 (0.41) | ADORA2ACYP3A4PDE1APDE1BPDE1C | |
| SCHEMBL13925884 | 0.73 | GLO1 (0.42) | CYP2A6CYP2B6CYP2E1ADORA2APTGER1 | |
| SCHEMBL13509085 | 0.73 | RECQL (0.38) | MAPTRECQLPDE1APDE1BPDE1C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7662779-B2 | Triazolyl macrocyclic hepatitis C serine protease inhibitors | ENANTA PHARMACEUTICALS, INC. (US) | 2010-02-16 | — | — | US | disclosed |
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090047248-A1 | TRIAZOLYL MACROCYCLIC HEPATITIS C SERINE PROTEASE INHIBITORS | SPINT2, PRSS1, CTSC | CYP2A6 308/4885CYP2B6 307/4885CYP2E1 161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.